hsa‑miR‑1‑3p and hsa‑miR‑361‑3p as potential biomarkers for onychomycosis: A pilot study

Meng,Li; Cai,Qing; Zhang,Huaijian; Gao,Zhiqin; Yang,Lianjuan

doi:10.3892/br.2024.1898

hsa‑miR‑1‑3p and hsa‑miR‑361‑3p as potential biomarkers for onychomycosis: A pilot study

Authors:
- Li Meng
- Qing Cai
- Huaijian Zhang
- Zhiqin Gao
- Lianjuan Yang
View Affiliations

Affiliations: Department of Dermatological Mycology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, P.R. China
Published online on: November 28, 2024 https://doi.org/10.3892/br.2024.1898
Article Number: 20
Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑coding small molecule RNAs are associated with a variety of diseases, including infectious diseases. However, small RNA‑related studies in onychomycosis have not been reported. The aim of the present study was to conduct an initial investigation of small RNA in onychomycosis. The present study collected a total of 33 affected nail samples from patients with onychomycosis and 18 normal nail samples from healthy people. Through RNA sequencing, 37 differentially expressed microRNAs (miRNAs or miRs), including 15 upregulated and 22 downregulated miRNAs, were identified in 3 patients with onychomycosis compared with 3 healthy controls. Moreover, three differentially expressed miRNAs were analyzed for further verification by RT‑qPCR in other 30 affected nail and 15 healthy nail samples. Among the three verified miRNAs, a significant difference between the downregulated hsa‑miR‑1‑3p and hsa‑miR‑361‑3p was observed (P<0.05). A total of 14,511 target genes of 37 differentially expressed miRNAs were predicted by the miRanda and RNAhybrid databases, while the Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analysis showed that these target genes were enriched in multiple signaling pathways. The present study indicated that hsa‑miR‑1‑3p and hsa‑miR‑361‑3p may be potential biomarkers for onychomycosis. Furthermore, the findings of the present study can be used in future research on RNA in onychomycosis.

View Figures

View References

1	Vlahovic TC: Onychomycosis: Evaluation, treatment options, managing recurrence, and patient outcomes. Clin Podiatr Med Surg. 33:305–318. 2016.PubMed/NCBI View Article : Google Scholar
2	Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A and Piraccini BM: Onychomycosis: A review. J Eur Acad Dermatol Venereol. 34:1972–1990. 2020.PubMed/NCBI View Article : Google Scholar
3	Hombach S and Kretz M: Non-coding RNAs: Classification, biology and functioning. Adv Exp Med Biol. 937:3–17. 2016.PubMed/NCBI View Article : Google Scholar
4	Lu TX and Rothenberg ME: Diagnostic, functional, and therapeutic roles of microRNA in allergic diseases. J Allergy Clin Immunol. 132:3–13. 2013.PubMed/NCBI View Article : Google Scholar
5	Miranda KC, Bond DT, McKee M, Skog J, Paunescu TG, Da Silva N, Brown D and Russo LM: Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 78:191–199. 2010.PubMed/NCBI View Article : Google Scholar
6	Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, et al: Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 3(e99263)2018.PubMed/NCBI View Article : Google Scholar
7	Wang J, Chen J and Sen S: MicroRNA as Biomarkers and Diagnostics. J Cell Physiol. 231:25–30. 2016.PubMed/NCBI View Article : Google Scholar
8	Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018.PubMed/NCBI View Article : Google Scholar
9	Leng N, Dawson JA, Thomson JA, Ruotti V, Rissman AI, Smits BM, Haag JD, Gould MN, Stewart RM and Kendziorski C: EBSeq: An empirical Bayes hierarchical model for inference in RNA-seq experiments. Bioinformatics. 29:1035–1043. 2013.PubMed/NCBI View Article : Google Scholar
10	Kruger J and Rehmsmeier M: RNAhybrid: MicroRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34:W451–W454. 2006.PubMed/NCBI View Article : Google Scholar
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
12	Rozalski M, Rudnicka L and Samochocki Z: MiRNA in atopic dermatitis. Postepy Dermatol Alergol. 33:157–162. 2016.PubMed/NCBI View Article : Google Scholar
13	Wu WB, Jiang XF and Chen MQ: microRNA-1-3p and T-synthase mRNA have high diagnostic efficacy on intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis. Kaohsiung J Med Sci. 39:732–739. 2023.PubMed/NCBI View Article : Google Scholar
14	Chen Y, Liu M, Jin H, Peng B, Dai L, Wang S, Xing H, Wang B and Wu Z: Synthetic evaluation of MicroRNA-1-3p expression in head and neck squamous cell carcinoma based on microarray chips and MicroRNA Sequencing. Biomed Res Int. 2021(6529255)2021.PubMed/NCBI View Article : Google Scholar
15	Tao S, Li H, Ma X, Ma Y, He J, Gao Y and Li J: Elevating microRNA-1-3p shuttled by cancer-associated fibroblasts-derived extracellular vesicles suppresses breast cancer progression and metastasis by inhibiting GLIS1. Cancer Gene Ther. 28:634–648. 2021.PubMed/NCBI View Article : Google Scholar
16	Lin Q: MicroRNA-1-3p affects lung adenocarcinoma progression through E2F8 and regulating NF-кB pathwayy. Cytokine. 156(155922)2022.PubMed/NCBI View Article : Google Scholar
17	Zhou H, Tang H, Li N, Chen H, Chen X, Gu L, Zhang L, Tian G and Tao D: MicroRNA-361-3p inhibit the progression of lymphoma by the Wnt/β-catenin signaling pathway. Cancer Manag Res. 12:12375–12384. 2020.PubMed/NCBI View Article : Google Scholar
18	Li J, Yang P, Chen F, Tan Y, Huang C, Shen H, Peng C, Feng Y and Sun Y: Hypoxic colorectal cancer-derived extracellular vesicles deliver microRNA-361-3p to facilitate cell proliferation by targeting TRAF3 via the noncanonical NF-κB pathways. Clin Transl Med. 11(e349)2021.PubMed/NCBI View Article : Google Scholar
19	Hua B, Li Y, Yang X, Niu X, Zhao Y and Zhu X: MicroRNA-361-3p promotes human breast cancer cell viability by inhibiting the E2F1/P73 signalling pathway. Biomed Pharmacother. 125(109994)2020.PubMed/NCBI View Article : Google Scholar
20	Ogawa H, Nakashiro KI, Tokuzen N, Kuribayashi N, Goda H and Uchida D: MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma. Cancer Sci. 111:1645–1651. 2020.PubMed/NCBI View Article : Google Scholar